Welcome to our dedicated page for Akari Therapeutics news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics stock.
Akari Therapeutics plc develops oncology antibody-drug conjugates built around RNA splicing modulator payloads. News about AKTX centers on its ADC platform, the PH1 payload technology, and lead program AKTX-101, a TROP2-targeted ADC studied in solid tumor models including bladder, lung and breast cancer. Updates also cover intellectual-property protection for the company’s payload chemistry and therapeutic applications.
Recurring company developments include preclinical data releases, oncology conference abstracts, strategic development collaborations, capital-structure disclosures, governance matters, and American Depositary Share program updates. As an ADR issuer, Akari’s news may also address ordinary-share and ADS mechanics tied to Nasdaq listing requirements and shareholder approvals.
Akari Therapeutics (Nasdaq: AKTX) released a CEO Corner discussing trends from the 2026 ASCO Meeting and its role in the evolving ADC 2.0 landscape.
Topics include KRAS-driven cancers, limitations of existing ADC payloads, Akari’s PH1 spliceosome-modulating platform, preclinical KRAS combination data, and plans for a Phase 1 trial of AKTX-101 by mid-2027.
Akari Therapeutics (Nasdaq: AKTX) discussed the breakthrough potential of AKTX-101 and its spliceosome-modulating ADC platform in a Virtual Investor “What This Means” segment following acceptance of its first abstract at the 2026 ASCO Annual Meeting.
Management highlighted preclinical synergy with a KRAS inhibitor in KRAS-mutated pancreatic cancer models, the PH1 payload platform, and a targeted Phase 1 first-in-human trial initiation by mid-2027.
Akari Therapeutics (Nasdaq: AKTX) reported positive preclinical data for its TROP2-targeting ADC AKTX-101 using the novel RNA spliceosome-modulating payload PH1 in KRAS-mutated pancreatic cancer models.
AKTX-101 combined with KRAS inhibitor adagrasib showed synergistic cytotoxicity in KRAS G12D and G12C cell lines, unlike comparator TROP2 ADCs with topoisomerase I payloads, which appeared antagonistic. Akari has begun IND-enabling studies and is aiming to start a Phase 1 trial by mid-2027.
Akari Therapeutics (Nasdaq: AKTX) priced a private placement expected to raise approximately $5.5 million in gross proceeds. The company will sell 1,470,588 ADSs or prefunded warrants, plus unregistered Series H, I and J warrants priced at $3.74 per ADS.
Akari plans to use net proceeds for working capital, general corporate purposes, and to advance lead ADC candidate AKTX-101 toward a first-in-human Phase 1 trial. Closings are expected in three tranches between May 27 and July 15, 2026.
Akari Therapeutics (Nasdaq: AKTX) will participate in a live webcast fireside chat at A.G.P.’s Annual Healthcare Company Showcase on Wednesday, May 20, 2026. President and CEO Abizer Gaslightwala will discuss the company’s differentiated ADC pipeline, its proprietary PH1 RNA splicing modulator payload platform, and lead TROP2-targeting ADC program AKTX-101. The event is virtual, with registration available online, and a live webcast accessible via the Presentations page in the Investors section of Akari’s website.
Akari Therapeutics (Nasdaq: AKTX) announced grant of European Patent No. 3684773B1 for its Thailanstatin-based RNA splicing modulator ADC payloads. The patent provides broad composition-of-matter protection across many European countries, reinforcing the PH1 payload platform that supports ADC candidates AKTX-101 (TROP2) and AKTX-102 (CEACAM5).
The protection strengthens Akari’s global IP estate alongside issued patents in the US and key Asian and other markets, and supports development of AKTX-101, now in IND-enabling studies with a Phase 1 first-in-human trial targeted by mid-2027.
Akari Therapeutics (Nasdaq: AKTX) announced Australian patent acceptance (Application No. 2024201765) covering composition-of-matter claims for proprietary 2nd-generation Thailanstatin analog PH1 payloads designed for ADC therapeutics.
The approval expands global IP alongside issued patents in the US, China, India, Japan, Israel, and Mexico and supports advancement of AKTX-101 and the ADC pipeline; AKTX-101 is in IND-enabling studies with a Phase 1 first-in-human trial targeted for late 2026/early 2027. The company cites a TROP2 ADC market opportunity of about $12B by 2033.
Akari Therapeutics (Nasdaq: AKTX) announced an abstract accepted for online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026. The abstract describes AKTX-101 combination synergy with a K-Ras inhibitor in KRAS-mutated pancreatic cancers. Publication is scheduled for May 21, 2026 at 5:00 PM ET. Akari said this is its first ASCO acceptance and supports advancement of AKTX-101 into Phase 1 by late 2026/early 2027.
Akari Therapeutics (Nasdaq: AKTX) reported positive preclinical results for AKTX-101, a TROP2-targeting ADC using a novel RNA splicing modulator payload (PH1). AKTX-101 showed sub-nanomolar potency in bladder and selected lung and breast cancer models and greater cytotoxicity versus TROP2 ADCs with Topoisomerase I inhibitor payloads.
The company plans an IND submission in Q4 2026 and initiation of a Phase 1 study in Q1 2027; data were presented at AACR 2026.
Akari Therapeutics (Nasdaq: AKTX) CEO Abizer Gaslightwala discussed the company’s strategic partnership with WuXi XDC, calling it a milestone that validates Akari’s PH1 spliceosome‑modulating payload platform.
The interview said the collaboration goes beyond a typical CDMO role, is expected to reduce execution risk and accelerate an IND filing for AKTX-101 to late 2026, and positions Akari within the evolving ADC market.